Next Article in Journal
Real-World Effectiveness and Safety of SDZ-ADL (Adalimumab Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Previous Article in Journal
Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours

Article Versions Notes

Biologics 2022, 2(3), 211-212;
Action Date Notes Link
article xml file uploaded 31 August 2022 12:51 CEST Original file -
article xml uploaded. 31 August 2022 12:51 CEST Update
article pdf uploaded. 31 August 2022 12:51 CEST Version of Record
article html file updated 31 August 2022 12:52 CEST Original file -
article html file updated 28 February 2023 11:40 CET Update
Back to TopTop